国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
23期
3567-3570
,共4页
齐拉西酮%精神分裂症%血糖%心电图%血脂%体重
齊拉西酮%精神分裂癥%血糖%心電圖%血脂%體重
제랍서동%정신분렬증%혈당%심전도%혈지%체중
Ziprasidone%Schizophrenia%Blood glucose%ECG%Serum lipid%Body weight
目的 探讨齐拉西酮对女性精神分裂症患者的安全性.方法 收集32例女性精神分裂症患者,给予齐拉西酮治疗观察6周,分别于治疗前及治疗后第2、4、6周末进行实验室及心电图检查,探讨该药对女性精神分裂症患者血脂、血糖、体重及心电图的影响.结果 治疗后精神分裂症患者甘油三酯、胆固醇及体重均较治疗前有明显升高,差异具有统计学意义(P＜0.05);治疗4周后精神分裂症患者QT及QTC间期均较治疗前有显著延长,差异具有统计学意义(P＜0.05).结论 齐拉西酮对女性精神分裂症患者血脂、体重及QT间期影响较大,对血糖影响较小.
目的 探討齊拉西酮對女性精神分裂癥患者的安全性.方法 收集32例女性精神分裂癥患者,給予齊拉西酮治療觀察6週,分彆于治療前及治療後第2、4、6週末進行實驗室及心電圖檢查,探討該藥對女性精神分裂癥患者血脂、血糖、體重及心電圖的影響.結果 治療後精神分裂癥患者甘油三酯、膽固醇及體重均較治療前有明顯升高,差異具有統計學意義(P＜0.05);治療4週後精神分裂癥患者QT及QTC間期均較治療前有顯著延長,差異具有統計學意義(P＜0.05).結論 齊拉西酮對女性精神分裂癥患者血脂、體重及QT間期影響較大,對血糖影響較小.
목적 탐토제랍서동대녀성정신분렬증환자적안전성.방법 수집32례녀성정신분렬증환자,급여제랍서동치료관찰6주,분별우치료전급치료후제2、4、6주말진행실험실급심전도검사,탐토해약대녀성정신분렬증환자혈지、혈당、체중급심전도적영향.결과 치료후정신분렬증환자감유삼지、담고순급체중균교치료전유명현승고,차이구유통계학의의(P＜0.05);치료4주후정신분렬증환자QT급QTC간기균교치료전유현저연장,차이구유통계학의의(P＜0.05).결론 제랍서동대녀성정신분렬증환자혈지、체중급QT간기영향교대,대혈당영향교소.
Objective To discuss the safety of Ziprasidone in female schizophrenia patients.Methods 32 cases of female schizophrenia were treated with Ziprasidone for 6 weeks.Laboratory examination and ECG examination were carried out before and 2,4,6 weeks after treatment.Investigated the influence of Ziprasidone on lipid,blood glucose,body weight and ECG in female schizophrenia patients.Results The levels of triglyceride,cholesterol and body weight of female schizophrenia patients after treatment significantly rose than those before treatment,with statistical significant differences (P ＜ 0.05); QT and QTC interval 4 weeks after treatment significantly prolonged,with statistical significant differences (P ＜ 0.05).Conclusion Ziprasidone has influence on serum lipid,body weight and QT interval in female schizophrenic patients,but not on blood glucose.
